Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin

Soft-tissue sarcomas (STS) are a heterogeneous group of rare solid tumors of mesenchymal origin. This paper reviews the current status of systemic treatment in advanced and metastatic soft tissue sarcomas, with an emphasis on trabectedin. Trabectedin is a unique type of chemotherapeutic agent with m...

Descripción completa

Detalles Bibliográficos
Autores principales: Desar, Ingrid M E, Constantinidou, Anastasia, Kaal, Suzanne E J, Jones, Robin L, van der Graaf, Winette T A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993282/
https://www.ncbi.nlm.nih.gov/pubmed/27574465
http://dx.doi.org/10.2147/CMAR.S86746
_version_ 1782449130668294144
author Desar, Ingrid M E
Constantinidou, Anastasia
Kaal, Suzanne E J
Jones, Robin L
van der Graaf, Winette T A
author_facet Desar, Ingrid M E
Constantinidou, Anastasia
Kaal, Suzanne E J
Jones, Robin L
van der Graaf, Winette T A
author_sort Desar, Ingrid M E
collection PubMed
description Soft-tissue sarcomas (STS) are a heterogeneous group of rare solid tumors of mesenchymal origin. This paper reviews the current status of systemic treatment in advanced and metastatic soft tissue sarcomas, with an emphasis on trabectedin. Trabectedin is a unique type of chemotherapeutic agent with multiple potential mechanisms of action. We discuss the putative mechanisms, as well as the toxicity and administration schedules of trabectedin, followed by its efficacy in first-line systemic therapy and beyond first-line systemic therapy.
format Online
Article
Text
id pubmed-4993282
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49932822016-08-29 Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin Desar, Ingrid M E Constantinidou, Anastasia Kaal, Suzanne E J Jones, Robin L van der Graaf, Winette T A Cancer Manag Res Review Soft-tissue sarcomas (STS) are a heterogeneous group of rare solid tumors of mesenchymal origin. This paper reviews the current status of systemic treatment in advanced and metastatic soft tissue sarcomas, with an emphasis on trabectedin. Trabectedin is a unique type of chemotherapeutic agent with multiple potential mechanisms of action. We discuss the putative mechanisms, as well as the toxicity and administration schedules of trabectedin, followed by its efficacy in first-line systemic therapy and beyond first-line systemic therapy. Dove Medical Press 2016-08-17 /pmc/articles/PMC4993282/ /pubmed/27574465 http://dx.doi.org/10.2147/CMAR.S86746 Text en © 2016 Desar et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Desar, Ingrid M E
Constantinidou, Anastasia
Kaal, Suzanne E J
Jones, Robin L
van der Graaf, Winette T A
Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin
title Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin
title_full Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin
title_fullStr Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin
title_full_unstemmed Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin
title_short Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin
title_sort advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993282/
https://www.ncbi.nlm.nih.gov/pubmed/27574465
http://dx.doi.org/10.2147/CMAR.S86746
work_keys_str_mv AT desaringridme advancedsofttissuesarcomaandtreatmentoptionscriticalappraisaloftrabectedin
AT constantinidouanastasia advancedsofttissuesarcomaandtreatmentoptionscriticalappraisaloftrabectedin
AT kaalsuzanneej advancedsofttissuesarcomaandtreatmentoptionscriticalappraisaloftrabectedin
AT jonesrobinl advancedsofttissuesarcomaandtreatmentoptionscriticalappraisaloftrabectedin
AT vandergraafwinetteta advancedsofttissuesarcomaandtreatmentoptionscriticalappraisaloftrabectedin

Ejemplares similares